ArticleNature communications2024
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 70 citations in OpenAlex.
- Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.Nature communications · 2025Trial
- The peripheral immune landscape of human breast cancer.Oncoimmunology · 2026Review
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Review
- Tertiary lymphoid structures in cancer: their development, composition, clinical prognosis, and the drivers of the anti-tumor responses.Molecular biomedicine · 2026Review
- Review
- Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clinical and translational medicine · 2026Review
- Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression.iScience · 2026Article
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context.Cancers · 2026Review
- Spatial architecture of tertiary lymphoid structures represents an independent prognostic dimension in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
- Advances in immunotherapies in ovarian cancer.Journal for immunotherapy of cancer · 2026Review
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- Spleen-targeted neoantigen mRNA vaccine induces ISG15Cell reports. Medicine · 2026Article
- TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with brain metastases.EBioMedicine · 2026Article
- Multi-armored mesenchymal stem cells potentiate antitumor immunity to combat ovarian cancer.Stem cell research & therapy · 2026Article
- Multiomics immune profiling of a patient-relevant orthotopic lung cancer model using SEPARATE-Seq.Nature communications · 2026Article
- NKG2A inhibition promotes NK cell-CD8Nature communications · 2026Article
- Association of CCL21Cancer immunology, immunotherapy : CII · 2026Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 11 institutions in 5 countries.
Lenka Kasikova *Sotio Biotech a.s., Prague, Czech Republic.
Jana Rakova *Sotio Biotech a.s., Prague, Czech Republic.
Michal HenslerSotio Biotech a.s., Prague, Czech Republic.
Tereza LanickovaSotio Biotech a.s., Prague, Czech Republic.
Jana TomankovaSotio Biotech a.s., Prague, Czech Republic.
Josef PasulkaSotio Biotech a.s., Prague, Czech Republic.ORCID http://orcid.org/0000-0001-6190-0465
Jana DrozenovaDepartment of Pathology, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Katerina MojzisovaSotio Biotech a.s., Prague, Czech Republic.
Anna FialovaSotio Biotech a.s., Prague, Czech Republic.ORCID http://orcid.org/0000-0003-1436-5142
Sarka VosahlikovaSotio Biotech a.s., Prague, Czech Republic.
Jan LacoThe Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Ales RyskaThe Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Pavel DundrDepartment of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Roman KocianDepartment of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Tomas BrtnickyDepartment of Gynecology and Obstetrics, 1st Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-6204-1903
Petr SkapaDepartment of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Linda CapkovaDepartment of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Marek KovarLaboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-6602-1678
Jan ProchazkaCzech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.ORCID http://orcid.org/0000-0003-4675-8995
Ivan PraznovecDepartment of Gynecology and Obstetrics, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Vladimir KoblizekDepartment of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Alice TaskovaDepartment of Thoracic Surgery, Charles University, 3rd Faculty of Medicine and Thomayer University Hospital, Prague, Czech Republic.
Hisashi TanakaDepartments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, West Hollywood, CA, USA.ORCID http://orcid.org/0000-0001-9223-4186
Robert Lischke3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Fernando Casas MendezOncology and Pneumology Department, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Jiri Vachtenheim3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-1468-4242
Viola Heinzelmann-SchwarzOvarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Francis JacobOvarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-0446-1942
Iain A McNeishOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-9387-7586
Michal J HalaskaDepartment of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Lukas RobDepartment of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
David CibulaDepartment of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Sandra OrsulicDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-5119-8721
Lorenzo GalluzziDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0003-2257-8500
Radek SpisekSotio Biotech a.s., Prague, Czech Republic.
Jitka FucikovaSotio Biotech a.s., Prague, Czech Republic. fucikova@sotio.com.ORCID http://orcid.org/0000-0002-8423-479X
Charles University · CZSotio (Czechia) · CZUniversity of Basel · CHCedars-Sinai Medical Center · USCornell University · USCzech Academy of Sciences · CZCzech Academy of Sciences, Institute of Molecular Genetics · CZOvarian Cancer Action · GBUniversity Hospital Hradec Králové · CZUniversity Hospital Kralovske Vinohrady · CZUniversity of California, Los Angeles · US
Funding
Mechanisms of gene amplification in human cancersR01CA149385 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI TANAKA, HISASHI · 2010 to 2022
$3.4MCancer-Associated Fibroblasts Alter the Composition of B Cells I Solid Malignancies - Diversity SupplementR01CA208753 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ORSULIC, SANDRA · 2016 to 2020
$2.2MBCCMA: Overcoming chemoresistance in ovarian cancer: Identification and validation of biomarkers and targetable drivers of platinum resistanceI01BX006020 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI SANDRA ORSULIC · 2023 to 2026
–BLRD VA I01 BX004974BLRD VA I01 BX006020NCI NIH HHS R01 CA149385NCI NIH HHS R01 CA208753
Abstract
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsOvarian NeoplasmsTertiary Lymphoid StructuresCD8-Positive T-LymphocytesFemaleHumansLymphocytes, Tumor-InfiltratingPhenotypeTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.